Compare Novavax Inc (NVAX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs BIO-TECHNE Corp — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 8.6× Novavax Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TECH | |
|---|---|---|
Market Cap | $1.30B | $11.16B |
Sector | Health | Health |
52-Week High | $11.19 | $72.12 |
52-Week Low | $6.22 | $43.31 |
Enterprise Value | $800.50M | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
